On this week’s Few & Far Between podcast episode, Biorasi’s CEO, Chris O'Brien, welcomes Karen Petrou and David Brint for an in-depth discussion on BioBonds and how they can jumpstart funding in clinical research for rare disease and other disorders.
Social media platforms and podcasts are spotlighting the untold stories of rare disease patients and their families. Find out more in today's Few &...
“Our studies are open for those that have exhausted standard of care, and we're showing improved responses, and the data is promising. So, I...
"In research or in biotech, time is expensive. Time is the most expensive thing that you have." - Stephanie Wisner, Author, Co-Founder at Centivax...